KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Other Accumulated Expenses (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Other Accumulated Expenses data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 37.0% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 37.0%, while the annual FY2025 figure was $2.0 million, 37.0% down from the prior year.
  • Other Accumulated Expenses reached $2.0 million in Q4 2025 per PACB's latest filing, up from $1.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $8.3 million in Q4 2023 and bottomed at $783000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $4.2 million, with a median of $4.1 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: soared 401.2% in 2021, then tumbled 84.85% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $5.8 million in 2021, then grew by 25.59% to $7.2 million in 2022, then grew by 15.11% to $8.3 million in 2023, then plummeted by 61.28% to $3.2 million in 2024, then crashed by 37.0% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $2.0 million in Q4 2025, $1.0 million in Q3 2025, and $2.6 million in Q2 2025.